In the autologous approach, a sample of a patient's blood is used to generate stem cells with nearly unlimited potential for expansion and differentiation into specialized cell types in our laboratories.
These “pluripotent” stem cells are securely banked and used to create gene-corrected healthy cells and tissues that can be reintroduced into the patient to recover biological function, support true regeneration, and cure disease at the root.
Disease target is confirmed and genetic mutation(s) causing the disease are identified
Cells are isolated from a small blood draw from the patient
Blood cells are reprogrammed into iPSCs using the ‘Yamanaka’ factors
Disease-causing genetic mutations are corrected ex vivo using CRISPR technology
Gene-corrected iPSCs are differentiated into disease-specific cell types and tissues
Healthy cells and tissues are transplanted back into the patient
Vita Therapeutics will soon be recruiting 15 patients for a first-in-human (FIH) clinical trial of VTA-100. Please monitor this site for more details on the trial and timing.